Dangnyangiwa Saramdeul to Build Pet Immunity-Based Healthcare Business Model with NKCL Bio Group, a Specialized NK Cell Therapy Company

Pet life-care platform company Dangnyangiwa Saramdeul announced on the 18th that it has signed a memorandum of understanding (MOU) with immune cell-based biotechnology company NKCL Bio Group for the joint development of pet healthcare and bio products, and has begun establishing an integrated business model combining AI-based data platforms with biotechnology.

Despite the rapid growth of the domestic pet market, healthcare, insurance, and commerce continue to operate in a fragmented structure, while data-driven services remain at an early stage. In particular, pet insurance penetration remains at approximately 1%, making it a representative untapped market with significant room for expansion.

Targeting this market structure, Dangnyangiwa Saramdeul is building an integrated model centered on its AI healthcare platform “Petcare 247,” connecting data → insurance → commerce → leisure.

A key competitive advantage secured through this collaboration is NKCL Bio Group’s NK cell-based immune biotechnology. The technology is regarded as a next-generation biotechnology applicable across various fields, including cancer treatment, immune enhancement, inflammation regulation, aging, and chronic disease response.

Based on this collaboration, the two companies plan to jointly develop and commercialize high-value product groups, including pet NK cell and stem cell therapeutics, immune enhancement products, functional nutritional supplements and healthcare solutions, as well as data-driven customized bio products.

Dangnyangiwa Saramdeul will also pursue a precision risk analysis-based pet insurance model utilizing health data accumulated on the platform. As the existing pet insurance market has faced growth limitations due to high loss ratios and low enrollment rates, the strategy is to improve the market through data-driven underwriting.

In addition, the companies aim to maximize customer lifetime value (LTV) by linking bio products with platform commerce to create a structure that leads from product experience to purchase.

An official from Dangnyangiwa Saramdeul stated, “This collaboration with NKCL Bio Group goes beyond simple product development and marks a starting point for transforming the pet industry into a data-driven industry. By combining AI platforms with immune biotechnology, we aim to establish a business structure expandable not only in Korea but also in the global market.”

The official added, “Our goal is to grow into an integrated platform encompassing pet healthcare, insurance, and commerce within the next three to five years and secure a unique position in the market.”